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Abstract
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance
inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form
of increased androgen receptor (AR) expression. Targeting proteins that are expressed as a
down-stream effect of AR activity is a promising rationale for management of this disease. The humanized
IgG1 antibody hu11B6 internalizes into prostate and prostate cancer (PCa) cells by binding to the catalytic
cleft of human kallikrein 2 (hK2), a prostate specific enzyme governed by the AR-pathway. In a previous
study, hu11B6 conjugated with Actinium-225 (225Ac), a high linear energy transfer (LET) radionuclide, was
shown to generate an AR-upregulation driven feed-forward mechanism that is believed to enhance
therapeutic efficacy. We assessed the efficacy of hu11B6 labeled with a low LET beta-emitter,
Lutetium-177 (177Lu) and investigated whether similar tumor killing and AR-enhancement is produced.
Moreover, single-photon emission computed tomography (SPECT) imaging of 177Lu is quantitatively
accurate and can be used to perform treatment planning. [177Lu]hu11B6 therefore has significant potential
as a theranostic agent.
Materials and Methods: Subcutaneous PCa xenografts (LNCaP s.c.) were grown in male mice.
Biokinetics at 4-336 h post injection and uptake as a function of the amount of hu11B6 injected at 72 h
were studied. Over a 30 to 120-day treatment period the therapeutic efficacy of different activities of
[177Lu]hu11B6 were assessed by volumetric tumor measurements, blood cell counts, molecular analysis
of the tumor as well as SPECT/CT imaging. Organ specific mean absorbed doses were calculated, using a
MIRD-scheme, based on biokinetic data and rodent specific S-factors from a modified MOBY phantom.
Tumor tissues of treated xenografts were immunohistochemically (IHC) stained for Ki-67 (proliferation)
and AR, SA-β-gal activity (senescence) and analyzed by digital autoradiography (DAR).
Results: Organ-to-blood and tumor-to-blood ratios were independent of hu11B6 specific activity except
for the highest amount of antibody (150 µg). Tumor accumulation of [177Lu]hu11B6 peaked at 168 h with
a specific uptake of 29 ± 9.1 percent injected activity per gram (%IA/g) and low accumulation in normal
organs except in the submandibular gland (15 ± 4.5 %IA/g), attributed to a cross-reaction with mice
kallikreins in this organ, was seen. However, SPECT imaging with therapeutic amounts of [177Lu]hu11B6
revealed no peak in tumor accumulation at 7 d, probably due to cellular retention of 177Lu and decreasing
tumor volumes. For [177Lu]hu11B6 treated mice, tumor decrements of up to 4/5 of the initial tumor
http://www.thno.org
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volume and reversible myelotoxicity with a nadir at 12 d were observed after a single injection. Tumor
volume reduction correlated with injected activity and the absorbed dose. IHC revealed retained
expression of AR throughout treatment and that Ki-67 staining reached a nadir at 9-14 d which coincided
with high SA- β-gal activity (14 d). Quantification of nuclei staining showed that Ki-67 expression
correlated negatively with activity uptake. AR expression levels in cells surviving therapy compared to
previous timepoints and to controls at 30 d were significantly increased (p = 0.017).
Conclusions: This study shows that hu11B6 labeled with the low LET beta-emitting radionuclide 177Lu
can deliver therapeutic absorbed doses to prostate cancer xenografts with transient hematological
side-effects. The tumor response correlated with the absorbed dose both on a macro and a small scale
dosimetric level. Analysis of AR staining showed that AR protein levels increased late in the study
suggesting a therapeutic mechanism, a feed forward mechanism coupled to AR driven response to DNA
damage or clonal lineage selection, similar to that reported in high LET alpha-particle therapy using 225Ac
labeled hu11B6, however emerging at a later timepoint.

Introduction
Castration resistant prostate cancer (CRPC) is
associated with poor prognosis and is often
characterized by sustained AR-signaling over the
entire course of disease progression. In fact,
‘castrate-resistant’ reflects continued androgen
dependence, rather than independence [1]. Thus,
much of the effort spent developing new
pharmacological compounds has been focused on
either AR blockade or androgen synthesis deprivation
with drugs such as apalutamide and abiraterone.
However, despite interventions with these drugs (and
often following an initial response), some form of
reactivation of the AR pathway inevitably occurs. The
radiotherapeutic we consider here follows an
alternate line of reasoning. Rather than attempting to
disrupt the AR-signaling, we take advantage of its
presence by targeting potent cytotoxic agents to
proteins resultant from AR pathway activation [2].
The use of radioimmunotherapy (RIT) has been
shown to be a successful treatment of liquid tumors
using anti-CD20 and CD33 antibodies [2,3].
Radionuclide therapy of CRPC patients using prostate
specific membrane antigen (PSMA) targeting
modalities are promising but might have severe
dose-limitations due to high expression and uptake in
off-target organs such as salivary glands and kidneys
[4-7].
Human kallikrein related peptidase 2 (hK2) is a
serine protease that is exclusively found in prostate
tissues (both healthy and malignantly derived) and is
known to have increased expression with the severity
of the disease [8-11]. KLK2, the gene encoding hK2, is
regulated by the AR pathway. In a manner similar to
that of the closely related kallikrein, Prostate specific
antigen (PSA), active hK2 is retrograde released into
the blood where it is immediately deactivated by
abundant protease inhibitors [12]. We have devised a
humanized targeting platform based on the
construction of an antibody, hu11B6, which is specific

for the catalytic cleft of active hK2. To date, we have
shown that hu11B6 specifically internalizes into hK2
expressing cells in vivo through a mechanism that
relies on the intact variable region, and on the
fragment crystallizable (Fc) region’s ability to bind to
the neonatal Fc receptor (FcRn) [13].
In a previous study, following therapy with
hu11B6 labeled with the high LET alpha-particle
emitting radionuclide Actinium-225 (225Ac), we
reported an increase in AR-activity and hK2
production in cells as an effect of DNA repair [14].
The AR flair phenomenon has initially been reported
based on Caesium-137 (137Cs) external beam radiation
[15, 16], and to our knowledge it has not been
previously demonstrated that low LET beta-emissions
generate the same effect. High LET alpha-particles
produce irreparable damage, i.e. DNA double strand
breaks (DSB), when traversing the nucleus compared
to low LET beta-particles which to a higher degree
indirectly damage the cell via the creation of reactive
oxygen species [17,18]. This oxidative stress results in
DNA single strand breaks (SSB) and a lower
frequency of DSB. However, the occurrence of an AR
flair phenomenon caused by low LET beta-particles
could potentially result in enhanced treatment
efficacies relating to a feed-forward mechanism. This
is of particular interest since various low LET
β-emitters are frequently used in radiotherapeutic
agents.
The overarching aim of the current study was to
gather dosimetric, therapeutic and radiobiological
data that will guide our upcoming clinical translation
of radiolabeled hu11B6. In this study we investigated
whole body and small-scale tumor dosimetry in an
animal model, as well as therapeutic and biological
effects of hu11B6 labeled with Lutetium-177 (177Lu), a
low LET beta-emitter with significant interest for
theranostic clinical RIT.

http://www.thno.org
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Materials and methods
Conjugation, radiolabeling and affinity
measurements of hu11B6
Conjugation, radiolabeling and stability studies
were performed as previously described [18]. In
summary, hu11B6 and non-specific isotype control
IgG1 were conjugated with p-SCN-Bn-CHX-A”-DTPA
(Macrocyclics, Dallas, TX), a backbone substituted
diethylenetriaminepentaacetic acid (DTPA) derivate
chosen as a trade-off between stability and metal ion
complexation [19], in a 1:3 molar ratio. 50 – 250 MBq
177LuCl (IDB Petten BV, Baarle-Nassau, Holland) was
3
added to 150 µg of hu11B6 (~1 µg/µL) in ammonium
acetate buffer (pH of ~5.5), with a final volume of 500
µL. After 2 h of incubation, free 177Lu was eluted from
177Lu-DTPA-hu11B6
([177Lu]hu11B6)
and
177Lu-DTPA-IgG ([177Lu]IgG ) using a NAP-5 column
1
1
(GE Healthcare, Uppsala, Sweden) equilibrated with
saline or PBS. Stability of [177Lu]hu11B6 was studied
by incubating samples (n = 3) in mouse serum at 37°C
for 1 w, using labeled conjugate in PBS as a control.
Separation was performed on NuPAGE®Bis-Tris Gel
(Life technologies via Thermo Fischer Scientific). The
conjugation and radiolabeling of the non-specific
antibody, an IgG antibody from mouse serum (Sigma,
I-8765), was performed as above. Binding affinity of
177Lu-hu11B6
was evaluated and compared to
non-labeled hu11B6 using Surface Plasmon
Resonance (SPR), see suppl. information.

Cell line
LNCaP-FGC was purchased from American
Type Culture Collection (ATCC, Manassas, VA) and
cultured according to their instructions.

Animal model
All animal experiments were performed in
accordance with the regional Ethics Committee's
requirements. Male BALB/c foxn1nu/foxn1nu (in
house) or NMRI foxn1nu/foxn1nu (Charles River
Laboratories, Wilmington, MA) were inoculated
subcutaneously in the right flank with the KLK2
expressing cell line LNCaP-FGC in a suspension of 1:1
mixture of RPMI-1640 media and Matrigel (BD
Biosciences, San Jose, CA). Due to the technical
difficulties of sampling enough blood related to the
size of BALB/c foxn1nu/foxn1nu mice, the relatively
larger NMRI nude mice were added to obtain a
complete picture of the blood status but not included
in the survival analysis.

Specific activity and biodistribution study
Mice bearing LNCaP s.c. xenografts (n = 3 - 4 per
group) were administered fixed activities of
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[177Lu]hu11B6 by tail-vein injections (0.4 - 0.6 MBq).
The mass amounts of hu11B6 injected were however
varied; 10, 30, 50, 100, 150 µg. Tumors, blood, and
organs were collected at 72 h post-injection. A
separate set of mice bearing LNCaP s.c. xenografts
was administered with a roughly fixed specific
activity of [177Lu]hu11B6 (20 - 30 µg of protein and 0.4
- 0.6 MBq of 177Lu) but in this case tumors, blood, and
organs were collected at 4, 24, 48, 72, 168 and 336 h
post-injection. Animals were euthanized using
intra-peritoneal injections of Ketalar-Rompun (10
µL/g, bodyweight), or via carbon dioxide inhalation,
followed by heart puncture and collection of blood.
Harvested tissues were weighed and measured in a
NaI(Tl) well counter (1480 Wizard, Wallac, Perkin
Elmer) and compared to radioactive standards. The
count data were background and decay corrected, and
uptake was expressed as percent injected activity per
gram of tissue (%IA/g).

SPECT/CT
A preclinical SPECT/CT scanner (NanoSPECT/
CT Plus, Mediso; Budapest, Hungary) equipped with
the NSP-106 multipinhole mouse collimator was used
and with energy windows of 20% centered over the
56-, 113-, and 208-keV energy peaks of 177Lu.
Acquisition time was about 40 min. Mice given
therapeutic amounts of [177Lu]hu11B6 and dedicated
for molecular tumor analysis (see section on
therapeutic efficacy) were imaged at 4, 7, 9 and 14 d (n
= 4) post injection. CT imaging was done before each
whole-body SPECT. SPECT data was reconstructed
using HiSPECT software (SciVis; Goettingen,
Germany). With the help of the CT images as an
anatomical reference, regions of interest (ROI), where
drawn for tumor, submandibular glands, liver and
heart using the VivoQuant 3.0 software (inviCRO;
Boston, MA). Activity data (MBq/mm3) was extracted
and then converted to percent injected activity per
gram of tissue (%IA/g) by assuming a tissue density
of 1.0 g/cm3.

Therapeutic efficacy
LNCaP tumor bearing mice (tumor > 3mm in
diameter) were randomized to one of seven groups,
with one group randomized for molecular tumor
analysis using pre-set euthanization time-points at 4,
9, 14 and 30 d after initiation of treatment and with
one group left untreated. All mice were administered
a single injection having a protein mass of 30 µg,
determined based on previous results [20] and on the
results of the aforementioned specific activity study.
Syringe activity (MBq) was measured before and after
injection (Atom Lab 500 Dose Calibrator, Biodex
Medical Systems Inc., Shirley, NY) to determine the
http://www.thno.org
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range of individually injected activity (Table 1).
Bodyweight and tumor volume (external caliper
measurement, V = 0.5 × length × width × width) were
monitored 2–3 times per week up to 120 d post
injection. For tumor size range at start of therapy, see
the Supplementary Information section. Relative
tumor size (RTS) was calculated as the natural
logarithm of the fractional increase in volume relative
to the tumor size at treatment start [21]. Tumor
diameter >15 mm, or severe decline in general
condition, were used as endpoints. The total white
blood cell counts (WBC), red blood cell counts (RBC)
and platelets (PLT) were measured twice weekly
during the first month. Blood samples (20 µL) were
collected from the tail vein and analyzed in an Exigo
Veterinary (Exigo Vet) Hematology Analyzer (Boule
Medical, Stockholm, Sweden).

Immunohistochemistry and androgen
receptor intensity analysis
After mice were euthanized, tumor tissue was
collected, portioned and cryo-preserved in optimal
cut temperature cryomount (Histolab Products AB,
Stockholm, Sweden), or first fixed in 4%
paraformaldehyde (PFA) solution and embedded in
paraffin before sectioning. Prior to staining for Ki-67
and AR, cryosections were dried for 15 min in 37°C
and then fixed with 4% PFA and quenched for 5-10
min using Dako REAL Peroxidase blocking solution
(Agilent Technologies, Santa Clara, Ca, US), then
incubated with rabbit anti-Ki-67 mAb (Clone SP6,
Thermo Fischer Scientific) or anti-AR mAb (ab133273,
Abcam, Cambridge, UK) respectively, followed by a 1
h incubation with horseradish peroxidase conjugated
Goat anti-rabbit F(ab)2 (111-036-045, Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA)
and
developed
with
Dako
liquid
DAB+
substrate-chromogen system (Agilent Technologies).
For detection of SA-β-gal activity, a marker of
senescence, the Abcam senescence detection kit
(ab65351) was used on cryosections first dried for 15
min in 37°C and then fixed in 1% formalin for 1 min
(fixative solution from kit). After counterstaining with
hematoxylin, or in the case of SA-β-gal activity, with
nuclear fast red solution (Sigma-Aldrich, Saint Louis,
Mo) and mounting with Pertex (Histolab), the sections
were imaged using a MIRAX MIDI automated whole
slide imager (Carl Zeiss AG, Oberkochen, Germany).
The Ki-67, AR and SA-β-gal stained sections were
independently evaluated by two skilled observers and
graded from no visible staining (-) to the most intense
staining (+++).
Sections from paraffin embedded blocks were
also used together with a modified AR staining
protocol where the concentration of anti-AR mAb was
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eight times lower than previously. This resulted in
tissue section images with a range of AR expression
intensities (as opposed to the effectively binary
staining achieved when high concentration of anti-AR
mAb was applied). These sections were analyzed as
follows. Masks selecting the AR expressing cells
within the images were generated using the Color
Threshold, Make Binary and Analyze Particle
functions within ImageJ [22]. These masks were then
applied to the original images (in RGB format) and
inverted mean-cell-intensities were calculated using
code written in Matlab (MATLAB and Statistics
Toolbox Release 2012b, The MathWorks, Inc., Natick,
Massachusetts, United States).

Macro- and small-scale dosimetry
Mean absorbed dose was calculated using a
previously
described
MIRD-scheme
with
mouse-specific S-factors [20, 23]. For calculation of
organ/tumor S-factors relevant for the used animal
model, a version of the MOBY phantom [24] was
applied. Actual organ sizes were used as input for the
S-value calculations using the Monte Carlo package
MCNP6. Bi-exponential curves were fitted to the
biokinetic data by least-square-fit to calculate the
time-integrated activity coefficient (see suppl.
information). The absorbed dose to the bone marrow
was calculated based on the assumption that the
activity concentration in red marrow is proportional
to blood at a ratio of 0.36 [25].
DAR of xenograft cryosections was performed
using a Biomolex 700 Imager (Biomolex AS, Oslo,
Norway) having an intrinsic spatial resolution of 50
µm and a 177Lu detection efficiency as previously
reported [26]. Corrections were applied for dead or
miscalibrated detector strips and radioactive decay.
To scale to specific uptake, each pixel was assumed to
contain a tissue volume of 50x50x8 µm3 and have a
density of 1.0 g/cm3. Autoradiographic images were
analyzed using IDL 8.5 (Exelis VIS, Harris
Corporation) and ImageJ. The absorbed-dose rate
distribution was calculated using a dose point kernel
(DPK) acquired by Monte Carlo simulation [27]. All
layers along one axis of the three-dimensional DPK
were summed to form a two-dimensional DPK that
includes contributions from assumed identical
activity distributions above and below the imaged
sections. The
image resolution was
then
down-sampled to 100 µm pixels to match the DPK
before convolution was performed to produce
absorbed-dose rate images. Correlation between
specific uptake or absorbed dose rate and cell
proliferation was evaluated by comparing three to six
ROIs, each about 1.3 ± 1.1 mm2, drawn using ImageJ
on each image along with an identical ROI in the
http://www.thno.org
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adjacent Ki-67 stained slide [28]. The intensity of
staining per nuclear area in these images was
determined using the ImageJ Immunoratio plugin [29]
with the threshold set to the maximum level to avoid
false positive classification of hemochromatic areas as
an effect of the RIT. Correlation was tested with the
non-parametric Spearman correlation measure using
IBM SPSS Statistics version 23.

Statistical and Image Analysis
Data are presented as the mean ±SD and
statistical significance was analyzed using the t-test,
unless otherwise noted. In all cases, differences in
results were taken to be statistically significant with
computed p < 0.05. Linear regression was applied to
evaluate treatment and dose response. Median
survival was calculated from Kaplan Meier graphs
generated with Prism 4. Statistical analyses were
performed using GraphPad Prism version 4
(GraphPad Software Inc., San Diego, CA), IBM SPSS
Statistics version 23 (SPSS Inc., Chicago, IL) and Excel
2016 (Microsoft).
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Results
Conjugation, Radiolabeling, Stability and
Affinity
The labeling yield for [177Lu]hu11B6 was 85.1 ±
5.2% (n = 7) with a radiochemical purity of >99% (n =
7). The stability of [177Lu]hu11B6 in plasma and PBS
was 68± 5% (n = 3) and 70% (n=1) at one week,
respectively. The affinity constant for conjugated
hu11B6 was not found to be significantly different
when compared to non-conjugated hu11B6 (p = 0.18)
(see suppl. information).

Specific activity and Biodistribution
Organ-to-blood ratios were largely unaffected by
specific activity except for at the highest amount of
antibody (150 µg), which resulted in higher uptake in
lung, spleen and muscle tissues (Figure 1A).
Tumor-to-blood ratios (Figure 1B) seem to be lower at
higher amounts of antibody, possibly due to
competitive inhibition, however they did not differ
significantly between the groups (non-parametric

Figure 1. A. The Organ-to-blood ratio for 10-150 µg labeled hu11B6 at 72h, uptake in the studied normal organs do not seem to change with increasing antibody amount
up to 150 µg. B. The Tumor-to-blood ratio for 10-150 µg labeled hu11B6 at 72h, the tumor to blood ratio varies and seem to be lower at higher amounts of antibody,
possibly because of competitive inhibition, however the variation is not statistically significant (p = 0.07). C. The Biokinetics of 177Lu-hu11B6 (20-30 µg). Tumor uptake
increased up to 1 w p.i. Generally, normal organs had far less accumulation of the tracer compared to tumor, except for the submandibular glands (as a cross-reaction between
human hK2 and a species specific kallikrein found in rodent salivary glands). D. Organ-to-blood ratio for 177Lu-hu11B6 versus time derived from data in Figure 1C.

http://www.thno.org
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Kruskal-Wallis test, p = 0.07). Peak tumor specific
uptake (29.1 ± 9.1 %IA/g) was noted at 1 w, and
maximum tumor-to-blood ratio 9.6 ± 6.1 was noted at
14 days, with blood clearance as the major reason for
this increase (Figure 1C-D), which corresponds well
with previously reported results [13, 20]. Uptake of
[177Lu]hu11B6 was also noted in the submandibular
glands. This finding is unrelated to humans and has
previously been reported as a possible cross-reaction
between 11B6 and a non-specified species-specific
kallikrein expressed in rodent salivary glands [13, 20].
The accumulation in the submandibular glands was
15 ± 5 %IA/g at one week which can be compared
with the residual activity in other normal organs at
between 0.2 -7.0 %IA/g at the same time (Figure 1C).
Compared to other non-kallikrein expressing organs,
clearance of [177Lu]hu11B6 was slower in the liver and
spleen, organs known to degrade full-sized antibodies
(Figure 1D).
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SPECT/CT
Representative SPECT/CT images for 4, 7, 9 and
14 days are displayed in Figure 2A. The specific
uptake (%IA/g) calculated from the SPECT
acquisition followed a different trend in xenografts as
compared to the biodistribution with subtherapeutic
amounts of activity (compare Figure 1C and Figure
2B). Instead of peaking at 7-9 d the specific uptake
continued to increase with time. The difference could
be explained by the therapeutic absorbed doses
delivered by the amount of [177Lu]hu11B6 used for
SPECT imaging. Over time this leads to decrease in
tumor volume, e.g. the group of mice imaged at 7 and
14 d, had a tumor size reduction of about 50% within a
week. This is further supported by the small change in
%IA for the same group (Figure 2C). The normal
organs follow a similar trend as compared to the
biodistribution, except for the submandibular glands
(compare Figure 1C and Figure 2B). This could be due
to the difficulty of drawing ROIs over the glands or
from effects of treatment reducing the specific uptake.

Figure 2. SPECT/CT imaging A. Representative maximum intensity projections of SPECT/CT of mice at 4, 7, 9 and 14 days p.i. of 177Lu-hu11B6. B.
Biokinetics as %IA/g of therapeutic amounts of 177Lu-hu11B6 (20-30 µg) quantified from SPECT data. Quantified data from SPECT/CT imaging of 177Lu-hu11B6 for
tumor, submandibular gland, liver and heart. The tumor biokinetics for therapeutic amounts of 177Lu-hu11B6 is different from that seen in Figure 1C, the %IA/g continues to
increase after 7d, probably as an effect of internalization of 177Lu-hu11B6 and tumor shrinkage following therapy. C. Quantified %IA data from SPECT/CT imaging of
177Lu-hu11B6. Evidently, while the group at nine days had a lower %IA/g it has a higher %IA. This is due to a somewhat larger tumor size in this group. It is probable that the
high uptake in the xenografts of this group reduces the amount of 177Lu-hu11B6 in other organs.

http://www.thno.org
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Figure 3. A. Kaplan-Meier survival curve for the therapy and control groups. Square: 177Lu-hu11B6, group A, with a median survival of 19 days. Triangle:
177Lu-hu11B6, group B, uncensored (all animals), median survival 77 days; Cross: 177Lu-hu11B6, group B, censored with a median survival beyond 120 days; Stars: unlabeled
hu11B6 median survival 44 days; Circle: 177Lu-non-specific mAb median survival 33 days; Diamond: Vehicle median survival 23 days. B. Hematopoietic toxicity for the
therapy group NMRI-foxn1nu/foxn1nu. From dosimetry the absorbed dose to bone marrow was estimated to 7.2-8.8 Gy showing a nadir at about 12 days for white blood
cells and 18 days for red blood cells where after recovery is seen. The absorbed dose to the tumor in this group was estimated to 56-68 Gy.

Therapeutic Efficacy
During the first 30 days of therapy the dominant
factor affecting survival was the pre-set tumor size
endpoint, not treatment toxicity, and survival is
therefore in general well reflected in the log(RTS) of
the different groups. Median survival in mice treated
with an absorbed dose of 48-53 Gy to the tumor (16.3 18.0 MBq of injected activity) was about twice the
average median survival of the control groups (Figure
3A). Unfortunately, some subjects had to be
euthanized prematurely due to non-tumor size
related health issues (tail necrosis resulting from the
blood sampling, eye infections and xenograft
ulceration). These cases were censored to obtain a
tumor growth relevant read-out of the therapeutic
effect (Figure 3A). Monitoring of the hematological
status in [177Lu]hu11B6 treated mice showed a
temporary decline during the first 12 days. At nadir
the levels of white blood cells, red blood cells and
platelets were 1.7± 1.0 109/L, 6.6± 1.2 1012/L and 207±
68 109/L, respectively (Figure 3B).
Compared to control groups ([177Lu]IgG1, vehicle
and non-labeled hu11B6), [177Lu]hu11B6 treated mice
showed a decrease in tumor volumes or significantly
reduced growth rates and xenografts given 48-53 Gy
to the tumor remained indolent between 25-60 days
(Table 1, Figure 4A and suppl. information Figure S2).
A single injection of [177Lu]hu11B6, corresponding to
tumor absorbed doses of 30-38 Gy (10.2 - 12.7 MBq of
injected activity), 48-53 Gy (16.3 - 18.0 MBq of injected
activity) and 56-68 Gy (18.9 - 23.1 MBq of injected
activity) at 25 days, resulted in RTS of 1.5 ± 0.2 (n =
10), 0.29 ± 0.07 (n = 8) and 0.22 ± 1.17 (n = 9),

respectively. In corresponding control groups, RTS in
[177Lu]IgG1, vehicle and non-labeled hu11B6 treated
groups were 2.4 ± 0.8 (n =8), 2.2 ± 0.4 (n = 10) and 6.6 ±
0.8 (n = 12), respectively, at 23 days. However, mice
receiving very high levels of activity (1650 ± 131
MBq/kg of [177Lu]hu11B6) had to be euthanized at
day 10−12 p.i. due to poor general condition. The
administrated activity to this group corresponds to a
bone marrow absorbed dose of 15-16 Gy, which is
above the reported maximum tolerable absorbed dose
to bone marrow in mice [30]. These results were not
found to be significantly different from previously
reported data based on 177Lu-labeled non-humanized
11B6 murine IgG1 and are included in Table 1 and
Figure 4A for comparison [20].

Dosimetry, DAR based small-scale dosimetry
and Immunohistochemistry
The average total tumor mean absorbed dose
calculated
from
biodistribution
data
was
approximately 3 Gy/MBq, which is approximately six
times higher than most normal organs. Importantly,
the total absorbed dose was only 0.4 Gy/MBq in bone
marrow, which is about 10 times lower than the
absorbed dose to the tumor (Table 1, S3 suppl.
information).
Analysis of DAR images showed that the mean
absorbed dose rate increased over the first 14 days of
the study period (Figure 5A). The small-scale
dosimetry performed on sections of tumors at
different time points revealed that there is a
heterogeneous absorbed dose rate distribution within
the tumor. As can be seen in Figure 5A, the maximum
and mean absorbed dose rates differ by as much as a
http://www.thno.org
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factor of five. This means that a portion of the tumor
receives much higher absorbed doses. The
comparisons with the mean absorbed dose rate
calculated from the biokinetics clearly show great
variability of absorbed dose rate, findings that could
not be discovered using a dosimetry based on
biodistribution data only. An increasing ratio of
maximum over mean absorbed dose rate over time
indicated that the activity concentrates into smaller
areas over the observed period (Figure 5B), which is to

be attributed to internalization and lysosomal
degradation of [177Lu]hu11B6 in target cells and a
decreasing number of vital cells per tissue area. This
conclusion is further supported by the SPECT data
(Figure 2B) where retention of [177Lu]hu11B6 as the
tumor decreases manifests as an increasing specific
uptake (%IA/g). During the earlier time-points, high
activity could be noted in stromal tissues representing
blood activity.

Table 1. The experimental design with amongst others the administered activity (MBq), specific activity (MBq/kg) and tumor and
bone marrow dosimetry for the [177Lu]hu11B6 therapy study with seven (A-G) groups of animals. Included are data from our previous
study with the murine 11B6 antibody [18]. The range of tumor volumes at therapy start are presented in table S1 in the supplementary
data. Administered amount of [177Lu]hu11B6 was 20-30 µg.
Group

n

Treatment

Administered
Activity (MBq)

BALB/c-foxn1nu/foxn1nu 177Lu-hu11B6
A
14 177Lu-hu11B6
11.0 ± 0.8
B
10 177Lu-hu11B6
17.1 ± 0.5
177Lu-hu11B6
C
9
41.2 ± 1.5
177Lu-ns- mAb
D
8
18.8 ± 2.2
E
12 hu11B6
–
F
13 Vehicle
–
NMRI-foxn1nu/foxn1nu 177Lu-hu11B6
G
21 177Lu-hu11B6
20.9 ± 1.3
NMRI-foxn1nu/foxn1nu 177Lu-m11B6***
177Lu-m11B6
H
5
10.1 ± 1.2
177Lu-m11B6
I
6
19.1 ± 1.4
177Lu-m11B6
J
3
36.2 ± 0.7

Specific Activity
(MBq/kg)

Weight at
injection (g)

Range of
Administered
Activity (MBq)

Range of Specific Range of Absorbed Range of Absorbed
Activity
Dose to tumor**
Dose to bone
(MBq/kg)
(Gy)
marrow** (Gy)

512 ± 85
674± 59
1650 ± 131
802 ± 140
-

22 ± 3
25 ± 3
25 ± 2
24 ± 2

10.2 – 12.7
16.3 – 18.0
39.5 – 42.3
13 – 20.5
–
–

425 - 704
610 - 782
1413 - 1804
550 - 950
-

30 – 38
48 – 53
117 – 124
-

3.8 – 4.9
6.2 – 6.9
15 – 16
-

586 ± 54.3

35.8 ± 2.8

18.9 – 23.1

483 - 670

56 – 68

7.2 – 8.8

330 ± 25
649 ± 102
1080 ± 68

30.6 ± 3.0
30.8 ± 3.0
33.7 ± 2.9

7.83 – 11.5
17.4 – 21.1
35.2 – 37.0

301 - 372
512 - 812
1000 - 1128

23 – 34
51 – 62
104 – 109

3.0 – 4.0
6.6 – 8.0
13 – 14

Values are, when applicable, presented as mean ± SD. * As calculated based on the biodistribution study shown in Figure 1C. and the average organ weights of the BALB/c
foxn1nu/nu therein. ***Original data published elsewhere, Vilhelmsson Timmermand et al. [18]

Figure 4. Linear regression of the logarithm of the relative tumor size (log(RTS) +/- SD). This method was applied for the initial 30 days’ growth and growth delay
data analysis. A. The log(RTS) over time for all the therapy groups with 177Lu-hu11B6. Also included the data previously presented [18] for the murine antibody 11B6. Both the
humanized and murine 11B6 shows similar therapeutic efficacy. Even though no tumor decrease in group A is observed, there is a growth delay compared to the controls (E, F,
D). B. The log(RTS) versus tumor absorbed dose, albeit at different dose rates, for all the therapy groups. As can be seen there is almost a linear correlation showing a similar
absorbed dose dependent therapeutic efficacy in all groups except in group A. This pattern is recognizable among data from both the humanized, hu11B6 (A, B, G) and the
previously published murine (H, I) antibody.
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Figure 5. Absorbed dose and activity and absorbed dose rate distributions in tumor sections compared to histology and Ki-67 staining, 1 – 30 days after
administration of 177Lu-hu11B6. A. Mean and maximum absorbed dose rate as measured in tumor sections together with mean tumor absorbed dose from macrodosimetry
calculated for the injected activity of the measured group. B. Absorbed dose rate ratio of Max to Mean. C. From left to right: Representative digital autoradiography images of
activity uptake individually scaled to %IA/g. The same tissue sections stained with hematoxylin and eosin. Adjacent sections stained for the proliferation marker Ki-67. Finally, the
distribution of absorbed dose rate at the moment of sacrifice, collectively scaled to mGy/h. From top to bottom 4, 9, 14 and 30 days after injection.

Histological scoring of tumor tissue showed
similar homogenous staining of AR at all timepoints
(Table 2). Staining for proliferation (Ki-67) and
senescence (SA-β-gal activity) appears to be
negatively correlated with low staining for Ki-67 at
9-14 days and high staining for SA-β-gal activity at 14
days (Table 2). Representative images of the SA-β-gal
activity stainings can be found in the suppl. material.
Although some variability was observed during the
time course, an overall correlation was noted between
increasing activity uptake and decreasing Ki-67
staining intensity (nadir at 9 and 14 days p.i.)
suggesting that [177Lu]hu11B6 inhibits cellular

proliferation (Table 2 and Table 3). In addition, at later
time-points higher activity was noted in fibrotic areas
surrounded by regions of low Ki-67 staining. No
activity uptake was found in necrotic tumor areas.
(Figure 5C). Analysis of the mean AR staining
intensity for each of the tissue section’s cells ranged
from 134 to 194 (arbitrary units). The results show that
the AR expression level remained roughly constant
over time up until two weeks but then at 30 days the
remaining viable cells had significantly greater AR
expression intensity (p = 0.017) compared to that of
the pooled data from the 4-14 day time points and the
controls (Figure 6A-B).
http://www.thno.org
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Figure 6. AR intensity analysis. A. Scatterplot with standard deviation and mean showing androgen receptor stain intensity which was pooled for controls (Ctrl) and 4-14 d
and displayed separately for 30 d after initiation of radioimmunotherapy. Each point represents the intensity mean for a tumor section taken from a single animal. The AR intensity
is significantly higher at 30 d indicating a AR flair phenomenon as result of DNA repair machinery. B. Representative tumor sections from which the data was derived. Top row
shows the AR expression stain levels as a function of time. Bottom row shows the masks used to select AR expressing cells for AR expression analysis.

Table 2. Ki-67, AR immunohistochemistry and SA-β-gal
activity staining. The intensity of the sections was graded
independently by two different observers on a scale from nothing
(-) to the highest intensity (+++). The average intensity is
presented in the table.
Days p.i.
4d
9d
14d
30d
Control

Average staining intensity
Ki-67
AR
++
+++
+
+++
+
+++
++
+++
+++
+++

SA-β-gal activity
++
++
+++
++
+

Table 3. Correlation between nuclei stained for
proliferation (Ki-67) and DAR image activity and
absorbed dose rate
Spearman correlation coefficient
Time p.i. (d) Ki-67 staining vs.
Ki-67 staining vs. absorbed-dose rate at the time
activity
of sacrifice
†
4
-0.548
-0.523†
9
-0.750†
-0.672†
14
-0.409
-0.379
30
-0.343
-0.346
†

p < 0.01

Discussion
Disabling the AR-signaling pathway has been
the central pillar of PCa treatment since the seminal
studies of Huggins and Hodges more than a
half-century ago [31]. The major downfall with
managing CRPC using this treatment strategy is the
rapid development of resistance. Despite combining
high affinity AR-blockers with steroid pathway
synthesis inhibitors, the increased median survival in
this patient group is only a couple of months. An
alternative treatment path is to target potent cytotoxic
agents to the sites of AR-driven PCa. We have
addressed this unmet need for sustainable treatment
effects by developing a radioimmunotherapeutic

platform targeting hK2, a tightly AR-regulated
prostate kallikrein. hK2 is a well characterized
protease, with 80% amino acid homology to PSA.
Other prostate-targeting agents lack specificity to
prostate-derived tissue with significant off-target
accumulation. Therefore, in vivo targeting of hK2 can
be a significant improvement over PSMA, which has a
high expression in non-target organs and in
radiosensitive tissues such as the kidney. This issue is
also prevalent among other targeting strategies, such
as bombesin/gastrin-released peptide receptor
(GRP-R) and prostate stem cell antigen (PSCA).
Off-target accumulation limits the utility of cytotoxic
radiolabeled small molecules and antibodies in
treating prostate cancer and calls attention to the need
for better engineered biologic delivery molecules.
Furthermore, the clinical impact of AR-directed
therapy on PSMA expression is poorly understood.
PSMA expression has been shown to increase with AR
inhibition [32] but also to decrease following long
term ADT with an uneven metastatic expression (45%
of metastatic lesions are PSMA-positive) [33].
Interestingly, in enzalutamide-resistant disease with
glucocorticoid receptor cross-activated AR pathway,
KLK2 (hK2) expression, but not KLK3 (PSA) or FOLH1
(PSMA), is restored [34], suggesting hK2 as an optimal
target for imaging and therapy.
Our previous reports, based on preclinical
studies in advanced GEM models of prostate
adenocarcinoma and metastatic disease, have shown
that intravenously introduced radio- or fluorescently
labeled 11B6 achieve uptake, internalization, and
lysosomal degradation in hK2 expressing cells
through an FcRn-mediated mechanism [13]. Cellular
internalization provides permanent deposition of
radionuclides in the cell. In this study we labeled
hu11B6 with177Lu, generating [177Lu]hu11B6, which
http://www.thno.org
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emits beta--particles at the site of the tumor.
Compared to short-range alpha-emitters (such as
Actinium-225, Bismuth-213 and Astatine-211), the
long-ranging betas from [177Lu]hu11B6 result in a
crossfire effect. This could potentially be lethal to
surrounding heterogeneous cell populations with
lower AR and lower target expression. Thus even
nearby cancer cells that do not internalize hu11B6 will
be irradiated. The capability of hu11B6 to deliver
payloads close to the nucleus, as compared to cell
membrane binding targeting, is of high importance
for the therapeutic efficacy when using alpha particle
emitters. Following internalization of [177Lu]hu11B6 to
the nucleus, a contribution from short ranged
conversion electrons to the resulting absorbed dose
can also be expected. 177Lu also emits two prominent
easily imaged medium energy photons (113 and 208
keV at 6.8 and 10.4% abundance, respectively) which
have been shown to produce images with a
quantitative accuracy of better than 5-6% [35, 36] and
can therefore be used in a theranostic approach to hK2
targeted RIT. Further, in a clinical setting, it is possible
that some patients might not benefit from the use of
this radioimmuoconjugate due to high serum levels of
free hK2. However, this could then be determined
with a simple blood test already conducted today.
Evaluating
the
therapeutic
efficacy
of
[177Lu]hu11B6 revealed that a single injection resulted
in good therapeutic response with acceptable overall
toxicity. The results are in line with our previously
reported results based on a murine version of 11B6
[20]. Interestingly, the relationship between
therapeutic efficacy, measured as log(RTS) and
absorbed dose to the tumor, is similar for most
administrated activities both in the present study and
in adapted data from our previous report (Figure 4B).
In clinical practice, potent and promising agents (such
as Radium-223) are administered on a per-weight
basis, without accounting for patient-specific disease
characteristics or the absorbed dose needed at lesions
to eradicate disease. Accounting for a dose-effect
relationship in targeted radionuclide therapy is
debated, although clinical studies have confirmed
dose-effect relationships, they are not very strong and
there are few preclinical studies that can demonstrate
clear relationships [37, 38]. This could in part be due
to the lack of accurate preclinical dosimetry models
[37]. In our study, the administrated activity and
absorbed dose versus log change in tumor volume
(log(RTS)) generally demonstrated a clear and
repeatable dose-effect relationship between tumor
response and relapse (Figure 3A and Figure 4A-B).
However, tumor specific uptake (%IA/g) acquired
from SPECT data deviates from that seen at 14 d when
using subtherapeutic amounts of activity (compare
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Figure 1C with 2B). This is because the volume of the
xenograft decreases as an effect of therapy which
means that the true absorbed dose to the remaining
tumor probably is higher than the one calculated
based on subtherapeutic activity biodistribution. A
similar effect has been shown clinically in lymphoma
patients [39]. However, at the same time the specific
uptake in heart and liver is similar with therapeutic
activities. The decrease in tumor volume and increase
over time in specific uptake, as observed with SPECT
imaging, confirms the functionality with respect to
internalization, retention and therapeutic efficacy of
[177Lu]hu11B6. Our findings therefore further support
a SPECT-based theranostic approach where
pre-therapy treatment planning can predict normal
organ toxicity and intratherapeutic dosimetry can
predict the therapeutic efficacy. This highlights the
need for robust and accurate dosimetry models in
preclinical evaluation of RIT compounds for solid
tumor treatment, thereby overcoming a significant
deficiency
in
the
existing
practice
of
radiopharmaceutical therapy agent translation and
application [40].
The heterogeneous absorbed dose distribution
following RIT implies that some malignant cells, not
directly targeted, could escape treatment. Or,
conversely, that there are areas within the tumor with
relatively high absorbed dose compared to the mean.
In this study, some absorbed doses reach values of
several hundred Gy, which could be an additional
explanation for good therapeutic results. We therefore
investigated the microdistribution of [177Lu]hu11B6
and found a dose-effect relationship between the
absorbed dose rate and the proliferation (Ki-67) in
different areas of the xenograft as well as an, over
time, increasing max-to-mean activity ratio between
different parts of the tumor (Table 3, Figure 5B).
However, though some tumor regions showed
varying degrees of response, histological staining and
absorbed dose rate distribution over time (Figure 5C)
together with the drastic decrease in tumor volume
reveals that large parts of the initially targeted tumor
are efficiently treated. The SPECT data on tumor
specific uptake and the data on changing
max-to-mean activity ratio support one another and
confirms the retention of the radionuclide in the
tumor over time. The retention of the radionuclide
and decreasing tumor volume is likely the reason for
retained absorbed dose rates within the tumor up to
14 days after injection (Figure 5C). Therapeutic effect
in an area of the tumor could thus lead to higher
absorbed doses in other parts of the tumor due to the
crossfire effect. The results show that both macro- and
small-scale dosimetry approaches and methods are
useful to fully understand the therapeutic response.
http://www.thno.org
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Uptake of [177Lu]hu11B6 over time could be
further stimulated by an increase in the AR axis
activity as an effect of therapy. The change in mean
AR staining intensity at 30 days points to a selection
mechanism or some pathway upregulation that
results in a net per-cell increase of AR protein level
following irradiation. As suggested in previous
studies, this could be due to a general increase in
DNA repair mechanisms dependent on AR
upregulation as a response to irradiation. This
phenomenon would then manifest itself later with
low LET beta-particles, post 14 days as opposed to
earlier reported 6-14 days for high LET alpha particles
[14]. Or it could be explained by the clonal selection of
cell lineages that use AR upregulation as a mechanism
of resistance. In our case this cell population would
then become dominant enough at 30 days to be
detected as an increase in mean AR staining intensity.
This theory could further explain the difference seen
between low LET beta-particles in this study and
previously studied high LET alpha particles.
Irradiation with low LET beta-particles results
predominantly in so called sub-lethal damage e.g.
SSB, as compared to high LET alpha particles which
mainly give rise to DSB. High LET irradiation has also
been shown to induce more apoptosis compared to
low LET irradiation [41] and to a faster cell death
progression due to more severe damage. Two weeks
into therapy we see large areas of cells stained for
SA-β-gal activity (Table 2) and low proliferation,
which together indicates senescence [42, 43]. A
senescent cellular state is an indefinite cell cycle arrest
as a consequence of irreparable sub-lethal damage e.g.
DNA damage or oxidative stress and the inability to
enter apoptosis [42]. Large numbers of senescent cells
in LNCaP xenografts after therapy with low LET
beta-particles could mask a clonal selection of lineages
with high AR expression by influencing the result of
measured mean AR status so that this phenomenon
appears to be delayed when compared to therapy
with high LET alpha-particles. The AR flair
phenomenon could therefore be the result of cells in
general responding to DNA damage by upregulation
of DNA repair pathways that involve the AR or from
subpopulations of cells that do so.
A potential therapeutic strategy, encouraged by
the enhanced AR expression several weeks after onset
of therapy, is to perform serial administration of
radiolabeled hu11B6. Our findings that AR protein
levels are increasing after [177Lu]hu11B6 therapy
(Figure 6), support earlier findings of increasing levels
of AR mRNA following [225Ac]hu11B6 therapy [14]
and points at a persistent and high AR signaling in
remaining cells following irradiation and hk2 targeted
RIT. This means that the response to treatment,

2140
instead of just conveying resistance, could lead to
continuously high uptake of hu11B6. However, it
remains to be further investigated how high and low
LET particle emissions, as well as different absorbed
dose rates, differ in their influence on this
radiobiological phenomenon. However, besides serial
administration, the parallel use of different
radionuclides with different LET is therefore also of
interest for further development. The combination of
therapy with both beta emitters and alpha emitters,
the later with high linear energy transfer and high
relative biological effect, as well as external beam
radiation therapy could be an interesting expansion of
the hK2 targeting RIT hu11B6 platform.

Conclusion
This preclinical study with 177Lu-radiolabeled
immuno-targeting of hK2 demonstrated good
therapeutic efficacy with one of the treated groups
showing a large reduction in tumor volume together
with reversible myelotoxicity. The tumor response
was dependent on administered activity and
delivered absorbed dose, as evaluated on both macro
and small-scale dosimetric levels. These results,
together with the findings of persistent hK2 and
increasing AR levels support the use of SPECT
imaging approaches for dosimetry and therapy
evaluation. Interestingly, hu11B6 radiolabeled with
177-lutetium, a low LET beta-emitter, appeared to
induce a similar AR flair phenomenon, albeit at a later
time point, in remaining prostate cancer cells as was
previously seen after [225Ac]hu11B6 treatment and
irradiation with a 137Cs source. In view of previously
published data, this study suggests that this could be
due to either a general DNA repair mechanism or
because of clonal lineage selection. The phenomenon
could potentially be used in therapeutic strategies
or
with
serial
[177Lu]hu11B6
parallel/co-administration of [177Lu]hu11B6 and
[225Ac]hu11B6.
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